Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IndexRUT P/E- EPS (ttm)-0.22 Insider Own4.21% Shs Outstand261.64M Perf Week0.82%
Market Cap966.50M Forward P/E49.73 EPS next Y0.07 Insider Trans-3.17% Shs Float251.57M Perf Month26.03%
Income-45.31M PEG- EPS next Q-0.01 Inst Own36.53% Short Float7.97% Perf Quarter80.39%
Sales184.91M P/S5.23 EPS this Y80.61% Inst Trans49.24% Short Ratio3.71 Perf Half Y100.00%
Book/sh0.09 P/B39.17 EPS next Y215.62% ROA-16.92% Short Interest20.05M Perf Year250.48%
Cash/sh0.43 P/C8.53 EPS next 5Y- ROE- 52W Range0.80 - 4.08 Perf YTD93.68%
Dividend Est.- P/FCF- EPS past 5Y32.58% ROIC-21.93% 52W High-9.71% Beta0.84
Dividend TTM- Quick Ratio2.02 Sales past 5Y-13.72% Gross Margin64.95% 52W Low360.00% ATR (14)0.20
Dividend Ex-Date- Current Ratio2.23 EPS Y/Y TTM3.07% Oper. Margin-11.91% RSI (14)64.49 Volatility2.35% 3.95%
Employees181 Debt/Eq8.39 Sales Y/Y TTM-1.24% Profit Margin-24.51% Recom1.00 Target Price7.40
Option/ShortYes / Yes LT Debt/Eq7.41 EPS Q/Q128.82% Payout- Rel Volume1.72 Prev Close3.56
Sales Surprise28.77% EPS Surprise178.95% Sales Q/Q75.84% EarningsMay 08 BMO Avg Volume5.41M Price3.68
SMA207.68% SMA5033.92% SMA20079.72% Trades Volume9,306,402 Change3.37%
Date Action Analyst Rating Change Price Target Change
Jun-04-25Resumed H.C. Wainwright Buy $8
Apr-28-25Initiated Leerink Partners Outperform $7
Apr-01-25Initiated Jefferies Buy $6
Nov-29-23Resumed BTIG Research Buy $4
Aug-28-23Upgrade H.C. Wainwright Neutral → Buy $3.75
May-31-23Upgrade Piper Sandler Neutral → Overweight $2 → $4
Mar-31-22Downgrade Piper Sandler Overweight → Neutral $8 → $2
Mar-31-22Downgrade Needham Buy → Hold
Mar-31-22Downgrade Mizuho Buy → Neutral $6 → $2
Mar-31-22Downgrade H.C. Wainwright Buy → Neutral $10 → $2
Jun-17-25 09:53AM
Jun-04-25 08:00AM
Jun-02-25 04:05PM
May-28-25 08:00AM
May-27-25 08:00AM
08:00AM Loading…
May-13-25 08:00AM
May-09-25 03:11AM
May-08-25 08:15AM
07:18AM
07:00AM
May-07-25 06:00PM
05:30PM
12:35PM
10:44AM
May-01-25 04:15PM
10:01AM Loading…
10:01AM
08:00AM
Apr-10-25 08:56AM
Apr-03-25 08:00AM
Apr-02-25 04:05PM
Mar-25-25 08:00AM
Mar-21-25 01:01PM
12:16PM
09:19AM
07:06AM
Mar-20-25 05:00AM
Mar-19-25 10:17PM
04:36PM
04:01PM
Mar-14-25 03:03AM
11:32PM Loading…
Mar-13-25 11:32PM
08:10AM
07:09AM
07:00AM
Mar-06-25 08:00AM
Mar-04-25 04:05PM
Feb-04-25 04:05PM
Jan-14-25 08:28AM
Jan-13-25 08:00AM
Jan-02-25 04:05PM
Dec-18-24 08:00AM
Dec-03-24 04:05PM
07:00AM
Nov-25-24 08:00AM
Nov-14-24 08:00AM
Nov-12-24 08:00AM
Nov-08-24 02:09AM
Nov-07-24 08:15AM
07:21AM
07:00AM
Nov-01-24 04:05PM
08:00AM
Oct-22-24 08:00AM
Oct-15-24 08:00AM
Oct-10-24 08:00AM
Oct-09-24 05:30PM
Oct-07-24 08:00AM
Oct-01-24 04:05PM
Sep-05-24 08:00AM
Sep-03-24 04:16PM
Aug-26-24 10:45AM
08:00AM
Aug-08-24 08:10AM
07:09AM
07:00AM
Aug-02-24 08:00AM
Aug-01-24 04:05PM
Jul-29-24 08:00AM
Jul-11-24 06:00AM
Jul-01-24 04:05PM
Jun-27-24 08:18AM
Jun-24-24 08:58AM
Jun-03-24 04:05PM
May-23-24 08:00AM
May-14-24 08:00AM
May-10-24 03:27PM
03:06PM
May-09-24 11:57AM
08:10AM
07:09AM
07:00AM
May-02-24 08:30AM
May-01-24 04:05PM
Apr-02-24 04:05PM
Mar-28-24 11:50AM
07:06AM
Mar-27-24 08:26PM
Mar-26-24 01:12PM
Mar-14-24 09:53PM
05:51PM
05:30PM
04:15PM
Mar-11-24 05:05PM
Mar-01-24 04:05PM
Feb-02-24 04:05PM
Jan-30-24 08:00AM
Jan-09-24 08:30AM
Jan-02-24 04:30PM
Dec-20-23 08:00AM
Dec-01-23 04:05PM
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Malabre Richard CSVP, Chief Accounting OfficerJun 09 '25Option Exercise1.6815,00025,200281,914Jun 11 05:13 PM
Malabre Richard CSVP, Chief Accounting OfficerJun 09 '25Sale4.0115,00060,150266,914Jun 11 05:13 PM
Malabre Richard CSVP, Chief Accounting OfficerJun 04 '25Sale3.5313,33447,069266,914Jun 05 04:35 PM
Butler John P.CEO and PresidentMar 03 '25Sale1.8346,40984,9282,557,921Mar 04 05:05 PM
Burke Steven KeithSVP, Chief Medical OfficerMar 03 '25Sale1.837,14413,074809,090Mar 04 05:04 PM
Burke Steven KeithOfficerMar 03 '25Proposed Sale1.837,14413,086Mar 03 05:39 PM
Butler John P.OfficerMar 03 '25Proposed Sale1.8346,40985,007Mar 03 05:37 PM
Butler John P.CEO and PresidentFeb 03 '25Sale2.10144,250302,9252,604,330Feb 04 05:54 PM
Burke Steven KeithSVP, Chief Medical OfficerFeb 03 '25Sale2.1050,506106,063816,234Feb 04 05:53 PM
Malabre Richard CSVP, Chief Accounting OfficerFeb 03 '25Sale2.1030,20263,424280,248Feb 04 05:52 PM
Grund NicholasChief Commercial OfficerFeb 03 '25Sale2.1055,621116,804442,579Feb 04 05:51 PM
Grund NicholasOfficerFeb 03 '25Proposed Sale2.1055,621117,060Feb 03 06:02 PM
Burke Steven KeithOfficerFeb 03 '25Proposed Sale2.1050,506106,295Feb 03 05:58 PM
Butler John P.OfficerFeb 03 '25Proposed Sale2.10144,250303,589Feb 03 05:50 PM
FRIESON RONDirectorJan 17 '25Option Exercise0.4520,1009,04593,800Jan 22 04:06 PM